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Background: Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of childbearing age.
The risk of pregnancy and neonatal complications in women with PCOS is debatable. In order to determine the risk
of pregnancy and neonatal complications, evidence regarding these risks was examined.
Methods: Literature searches were performed in the electronic databases MEDLINE, EMBASE, and CENTRAL based on the
established strategy and eligible tries were included according to inclusion and exclusion criteria. A systematic literature
review looking at rates of gestational diabetes mellitus (GDM), pregnancy-induced hypertension (PIH), preeclampsia,
premature delivery, neonatal birth weight, caesarean section and admission to a neonatal intensive care unit (NICU) was
conducted in women with PCOS. Pregnancy outcomes between women with PCOS versus controls were included.
Sensitivity analyses were performed to determine the reliability of the available evidence and to validate the results. The
study was performed with the approval of the ethics committee of the First Affiliated Hospital of Guangxi Medical University.
Results: A total of 27studies, involving 4982 women with PCOS and 119692 controls were eligible for the meta-analysis.
Women with PCOS demonstrated a significantly higher risk of developing GDM (OR3.43; 95% CI: 2.49–4.74), PIH (OR3.43;
95% CI: 2.49–4.74), preeclampsia (OR2.17; 95% CI: 1.91–2.46), preterm birth (OR1.93; 95%CI: 1.45–2.57), caesarean section
(OR 1.74; 95% CI: 1.38–2.11) compared to controls. Their babies had a marginally significant lower birth weight
(WMD −0.11g; 95%CI: -0.19 – -0.03), and higher risk of admission to NICU (OR 2.32; 95% CI: 1.40–3.85) compared to controls.
Conclusions: Women with PCOS have increased risk of adverse pregnancy and neonatal complications. It is necessary
to establish guidelines for supervision during pregnancy and parturition to prevent these complications.
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Polycystic ovary syndrome (PCOS) is a common and com-
plicated female endocrinopathy that estimated prevalence
varies from 3%–20% depending on the diagnostic criteria
used [1]. The most common features of PCOS are abnor-
mal ovulation, clinical or laboratory indices of increased
androgen levels, and polycystic ovaries on ultrasonography.
Clinical manifestations of PCOS are menstrual irregu-
larity (oligomenorrhea or amenorrhea), hirsutism, persistent
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reproduction in any medium, provided the orhypertension and infertility [2]. Although the prevalence
of PCOS and diversified clinical symptoms are known,
the exact pathogenesis of PCOS is not fully recognized yet.
It is commonly believed that insulin resistance, hyper-
androgenism and obesity play a significant role on the
pathophysiologic process of PCOS [3,4]. Insulin resistance
is universally accepted as one of the key biochemical features
of PCOS supported by complementary hyperinsulinemia,
and is associated with ovarian secretion disorder increas-
ing the androgen production by theca cells that lead to
hyperandrogenism [5,6]. Obesity, a characteristic of 60–80%
of PCOS patients, has a malignant additive effect on
features of PCOS such as insulin resistance, hyper-
androgenism, infertility, hirsutism and pregnancy compli-
cations [7]. However, the definite phenotype of PCOS. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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genism, polycystic ovaries), as well as the extent of obesity
in PCOS patients influences the variation of insulin re-
sistance level [8,9]. Furthermore, the interaction of insu-
lin resistance, hyperandrogenism and obesity results in
an increased risk of diabetes mellitus type 2 (DM2), meta-
bolic syndrome (MS), cardiovascular diseases (CVD), preg-
nancy loss and late pregnancy complications (preeclampsia,
gestational diabetes). This indicates that PCOS is a chronic
disease that impacts women across the lifespan [10].
Nowadays a growing body of evidence points to a high
prevalence of pregnancy complications in PCOS women.
As a result, PCOS is not only related to metabolic abnor-
malities, menstrual irregularity or infertility as previously
reported, but becoming increasingly recognized the prob-
lems of gestational diabetes (GDM), pregnancy-induced
hypertension, preeclampsia, premature delivery rate, neo-
natal birth weight, caesarean section rate, and rate and
admission to an NICU, which are all considered to be
adverse pregnancy outcomes of PCOS during pregnancy
[11-13]. The elevated risk for adverse obstetric compli-
cations that was observed in women presenting PCOS
varied widely depending on the different phenotypes and
features of PCOS [14]. Women with PCOS tend to require
ovulation induction or assisted reproductive technology
(ART) in order to become pregnant due to oligo-ovulation
or anovulation, this treatment for infertility often results
in an evaluated rate of multiple births [15,16]. In order
to explore the relationship between PCOS and preg-
nancy outcomes completely, the use of metformin, ovu-
lation induction or ART must be taken into account.
There have been a number of relevant studies performed
in order to illustrate incidences of pregnancy and neonatal
complications. However, the results of these studies have
often been inconsistent, and two previous meta-analyses
published on this issue have been questioned for the
statistical heterogeneity [17,18]. To derive a more precise
estimation of the risks of obstetric complications in
women with PCOS, a further meta-analysis with updated
data should be made. Therefore, we conducted an updated
meta-analysis using different statistical methods exist for
combining the data, to reassess the risks of pregnancy
and neonatal complications in women with PCOS ver-
sus controls. To the best of our knowledge, no meta-




To select qualified studies, a search was performed in the
electronic databases MEDLINE, EMBASE, and Cochrane
Central Register of Controlled Trials (CENTRAL) from
1966 through July 2012, the search strategy was conducted
depend on various combinations of the terms [‘PolycysticOvary Syndrome’ (MeSH) OR Hyperandrogenism (MeSH)]
AND [‘obstetric outcomes’ (MeSH) OR ‘Pregnancy Out-
come’ (MeSH) OR ‘Pregnancy Complications’ (MeSH)
OR ‘Diabetes Mellitus, Type 2’ (MeSH)OR PIH OR pre-
eclampsia OR preterm labor OR GDM OR fetal outcome
OR neonatal outcome] with no language limitation. And
then a manual search of the abstracts from the major an-
nual meetings in the field about Human Reproduction.
The main search was completed independently by two
reviewers (Lihong Pang and Junzhen Qin.). Discordance
was settled by consultation of a third reviewer (Mujun Li).
The inclusion and exclusion criteria are presented in
Table 1.
Eligibility of relevant studies
The main search strategy identified 1085 publications, 998
publications were excluded because of duplication or obvi-
ously irrelevance by title, then 41 articles were excluded
on the basis of the abstract. Of the remaining 46 articles
which were read in full by two reviewers independently in
strict accordance with the described selection criteria.
19 articles were excluded because 6 lacked selection cri-
teria, 3 did not evaluate the included outcomes, and 10
involved the use of metformin during pregnancy. Even-
tually, 27 studies were eligible for the meta-analysis (see
Figure 1).
Data extraction
Data extraction was conducted from all relevant studies
independently by two reviewers. Information was classi-
fied summarized as follow: general characteristics (author,
year of publication, study design, study center, study size
and ratio of cases to controls), characteristics of the PCOS
and control groups (method of conception, multiple preg-
nancies, and whether matched for age, body mass index
or parity). Try best to communicate with the authors
when data incomplete. Major characteristics are summed
up in Table 2 ‘see Additional file 1: Table S1’.
Statistical analysis
odds ratios (OR) with 95% confidence intervals (CI) for
dichotomous data, weighted mean difference (WMD) with
95% CI for Continuous data, and both combined with use
of a fixed-effects or random-effects model, where appropri-
ate. Heterogeneity between the results of different studies
was detected byχ2 tests for significance (a P value of <0.1
was considered statistically significant) and I2 test (I2 <25%:
insignificant heterogeneity, I2 >50%: significant heterogen-
eity). The Egger test was used for evaluating the degree
of publication bias. To prove reliability of the available
evidence and get convincing results, sensitivity analyses
were manipulated with the exclusion of studies with
borderline eligibility. Discordance among reviewers on
studies with borderline eligibility was resolved by consensus.
Table 1 Inclusion and exclusion criteria in examination of studies
Inclusion criteria Exclusion criteria
1. Diagnosis of PCOS accordance with to the NIH,
Rotterdam or AES criteria.
1. Studies that included women with preexisting diabetes mellitus
or Hypertension.
2. Use of women without PCOS as controls. 2. Metformin was used by the PCOS group after conception.
3. End points include GDM, PIH, PE, preterm, birth weight,
caesarean section or admission to NICU.
3. Multiple pregnancy rate was significantly different in the
two groups.
NIH National Institutes of Health [19], AES the Androgen Excess Society [20].
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than 10, univariate meta-regression analyses were performed
on the effect of a study-level characteristic to guarantee ex-
plainable outcomes. Meta-analysis and meta-regression were
conducted using Stata/SE 12.0 for Windows (StataCorp LP,
College Station, USA).Results
A total of 27 studies, involving 4982 women with PCOS
(4994 pregnancies) and 119692 controls (1,196,775 preg-
nancies), were eligible for the systematic review and meta-
analysis. The smallest study size of included studies is 34
[43], the maximal number is up to 1195123 [42].Studies identified by   
the main search 
(n = 1085) 
Studies excluded on 
duplication and title 
review    (n = 998) 
Studies screened by 
abstract review 
(n = 87 )
Studies excluded on an 
abstract basis  
 (n= 41 ) 
Full-text articles assessed 
for eligibility 
(n = 46 ) 
Studies excluded on 
full-text  basis      
(n = 19  ) 
Studies included in    
meta-analysis      
(n = 27 ) 
Figure 1 Flow diagram of included studies for this meta-analysis.Systematic review
Main characteristics of eligible studies are summarized
in Table 2. All the studies mentioned age, BMI, as well
as multiple pregnancies. The diagnostic standard of PCOS
is accordant with NIH 1990 criteria, the Rotterdam 2003
criteria or the AES 2006 criteria. Most of the studies were
retrospective in design, only 10 studies (37.0%) were pro-
spective. A total of 3 studies (11.1%) were multicenter, 1
study did not state whether it was multi- or single center,
and the rest were single center. The definitions of preg-
nancy and neonatal complications: gestational diabetes
mellitus is mainly diagnosed with a 50–100 g oral glucose
challenge test; pregnancy-induced hypertension depends
on BP ≥ 140/90 mmHg without proteinuria at a gesta-
tional age of >20 weeks; preeclampsia according to cri-
terion with BP ≥ 140/90 mmHg with proteinuria >0.3 g/
24h /≥2 + albustick at a gestational age of >20 weeks;
premature delivery (gestational age <37 weeks); birth
weight (g).
It is noted that higher valid studies are designated when
confounding variables (BMI, multiple pregnancies rate,
and selection of controls) are managed in PCOS and
control group. In 10 of 27 studies, the mean BMI of PCOS
women was significantly higher than that of controls.
Among the other 17 studies mean BMI was matched in
the two groups. In 6 studies there was an equal inci-
dence of multiple pregnancies in both study groups. In
one study, the outcomes of multiple and single pregnan-
cies were separate. In the remaining studies, only single
pregnancy was recorded. Of the 27 studies, 21 selected
women who became pregnant naturally (with no infer-
tility treatments) as controls, 5 included women who
had infertility treatments, and 1 did not describe the
controls. Beyond that, method of conception was not
mentioned for the PCOS group in 11.1% studies, whereas
in the remaining 89.9% studies ovulation induction or
assisted reproduction techniques (ART) were used for
conception in PCOS patients.
Among the total studies, significantly increased risks
of PCOS patients compared with controls were found in
11/21 studies GDM, 7/14 studies PIH, 5/15 studies pre-
eclampsia, 1/14 studies preterm, 5 /19 studies birth weight,
3/ 10 studies caesarean section and 1/5 studies admission
to an NICU. Consequently, the relationship between
PCOS and obstetric complications seem not robust
Table 2 Main characteristics of included studies
Study
no.
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6 Lesser [26] 1997 Retrospective single center 68 24/44 GDM Pregnant by CC, hMG infertility women
pregnant by CC,
hMG
Not stated PCOS higher BMI
















Not included Matched for age
and BMI




Not stated Similar BMI, age,
parity























12 Bjercke [11] 2002 Prospective single center 407 52/355 GDM,PIH,PE,preterm,
birthweight, Cesarean
section, NICU
Pregnant by CC, hMG,
IVF, IUI
Pregnant by ART Not included PCOS higher BMI












14 Turhan [33] 2003 Retrospective single center 174 38/136 GDM,PIH,PE,preterm,
birthweight, Cesarean
section,NICU
Not stated Normal pregnant
Women
Not included matched for age
15 Weerakiet [34] 2004 Retrospective single center 311 47/264 GDM,PIH,PE, preterm,
birthweight, Cesarean
section






















Table 2 Main characteristics of included studies (Continued)
16 Sir-Petermann [35] 2005 Prospective single center 227 47/180 GDM,PE, preterm,
birthweight, NICU
Not stated Normal pregnant
Women
Not included matched for age,
BMI







Not included PCOS higher BMI
18 Hu [37] 2007 Prospective single center 44 22/22 PIH, Birthweight Spontaneous Normal pregnant
Women




2007 Prospective single center 99 48/51 GDM,PIH Not stated Normal pregnant
Women
Not stated matched for age
20 Maliqueo [39] 2009 Prospective single center 64 30/34 Birthweight Spontaneous Normal pregnant
Women
Not included PCOS higher BMI




Not included matched for age,
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Pregnant by ART Normal pregnant
Women
Not included PCOS higher BMI
25 Dmitrovic [43] 2011 Prospective single center 34 17/17 GDM, Birthweight Not stated Not stated Not included results adjust for
BMI
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parity, BMI
GDM gestational diabetes mellitus, PIH pregnancy-induced hypertension, PE preeclampsia, NICU admission to a neonatal intensive care unit, ART assisted reproductive technology, IVF In vitro fertilization, CC clomifene,
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the adverse risk of pregnancy and neonatal complications
in women with PCOS, we have performed a systematic re-
view and meta-analysis of the best available trials.
Meta-analysis
Gestational diabetes mellitus
There were 21 studies, involving 4841 women with PCOS
and 1196705 controls, eligible for the meta-analysis on theFigure 2 OR for incidence of GDM in women with PCOS and controls
studies excluded.risk of development of GDM. Women with PCOS demon-
strated a significantly elevated chance of developing GDM
when compared with controls, yet with significant between-
study heterogeneity [21 studies, random effects OR 2.81
(95% CI: 1.99–3.98) heterogeneity χ2: P=0.001, I2= 57.0%;
Figure 1]. Publication bias was insignificant using the
Egger test (P=0.53). It was noted that, with the exclusion
of 4 studies with borderline eligibility [23,32,33,36], the
sensitivity analysis ‘see Additional file 2: Figure S1’, did. 01 Incidence of GDM all studies included. 02 borderline eligible
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P=0.229, I2= 19.2%), and the difference in the risk of de-
velopment of GDM between women with PCOS and con-
trols remained robust [17 studies, fixed effects OR 3.58 (95%
CI: 3.05–4.20) Figure 2]. Meta-regression failed to provide
evidence of a significant effect between outcome and
study type (retrospective vs. prospective) (P=0.18) or BMI
(P= 0.974).
Pregnancy-induced hypertension
There were 14 studies, involving 991women with PCOS
and 2682 controls eligible for the meta-analysis on the
risk of development PIH. Women with PCOS demon-
strated a significantly higher chance of developing PIH,Figure 3 OR for incidence of PIH in women with PCOS and controls. 01 Iyet with significant between-study heterogeneity [14 studies,
random effects OR 3.07 (95% CI: 1.81–5.18); heterogeneityχ2:
P=0.002, I2= 59.7%; Figure 3]. Publication bias was detected
significant by using the Egger test (P= 0.03). It was notable
that sensitivity analysis ‘see Additional file 3: Figure S2’
with the exclusion of one study with borderline eligibil-
ity [44], did substantial decrease in insignificant hetero-
geneity (χ2: P=0.309, I2= 13.5%), and the difference in
risk of development PIH between women with PCOS
and controls remained robust [13 studies, fixed effects
OR 3.43 (95% CI: 2.49–4.74), Figure 2]. Meta-regression
failed to provide evidence of a significant effect between
outcome and study type (retrospective vs. prospective)
(P=0.17) or BMI (P= 0.54).ncidence of PIH all studies included. 02 borderline eligible studies excluded.
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There were 15 studies, involving 4564 women with PCOS
and 1194098 controls eligible for the meta-analysis of the
risk of developing PE. Women with PCOS demon-
strated significantly elevated chance of developing PE,
yet with significant between-study heterogeneity [15 studies,
random effects OR3.28 (95% CI: 2.06–5.22) heterogeneityχ2:
P= 0.045, I2= 41.8%; Figure 4]. Insignificant publication
bias was detected either by using the Egger test for publi-
cation bias (P=0.32).Sensitivity analysis ‘see Additional
file 4: Figure S3’ with the exclusion of one study with
borderline eligibility [21], did substantial decrease in in-
significant heterogeneity (χ2: P= 0.131, I2= 30.7%), theFigure 4 OR for incidence of PE in women with PCOS and controls. 01 Idifference in risk of development PE between women
with PCOS and controls remained robust [14 studies,
fixed effects OR 2.17 (95% CI: 1.91–2.46) Figure 3]. Meta-
regression failed to provide evidence of a significant effect
between outcome and study type (retrospective vs. pro-
spective) (P= 0.06) or BMI (P= 0.34).
Premature delivery rate
There were 14 studies, involving 9719 women with PCOS
and 192866 controls eligible for the meta-analysis of the
risk of preterm. There was no significant difference in the
risk of delivering prematurely in women with PCOS vs.
controls, yet with significant between-study heterogeneityncidence PE all studies included. 02 borderline eligible studies excluded.
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heterogeneity χ2: P= 0.000, I2= 94.5%; Figure 5]. Publica-
tion bias was insignificant using the Egger test (P=0.32).
However, the risk of developing preterm between PCOS
and controls was significantly different [12 studies, fixed
effects OR 1.93 (95% CI: 1.45–2.57) Figure 4], by means
of sensitivity analysis ‘see Additional file 5: Figure S4’
with the exclusion of two studies with borderline eligi-
bility [32,42], and a substantial decrease in insignificant
heterogeneity (χ2: P= 0.198, I2= 25.0%). Meta-regression
failed to provide evidence of a significant effect between
outcome and study type (retrospective vs. prospective)
(P= 0.94) or BMI (P= 0.75).Figure 5 OR for incidence of preterm rate in women with PCOS and c
studies excluded.Birth weight
There were 19 studies, involving 899 women with PCOS
and 5401 controls, eligible for the meta-analysis compar-
ing birth weight. There was no significant difference in
neonatal birth weight in women with PCOS vs. controls,
yet with significant between-study heterogeneity [19 studies,
random effects WMD −0.14 (95% CI:-0.33–0.06) hetero-
geneity χ2: P= 0.000, I2= 81.5%; Figure 6]. Significant publi-
cation bias was not detected using the Egger test (P= 0.65).
Sensitivity analysis ‘see Additional file 6: Figure S5’ did sub-
stantially decrease insignificant heterogeneity (χ2: P= 0.131,
I2= 28.6%) with the exclusion of two studies with border-
line eligibility [37,39], so that infants from women withontrols. 01 Preterm rate all studies included. 02 borderline eligible
Figure 6 WMD for birth weight in women with PCOS and controls. 01 Incidence of birth weight all studies included. 02 borderline eligible
studies excluded.
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weight, though this was marginal [17 studies, fixed effects
WMD −0.11 g (95% CI: -0.19 – -0.03) Figure 5]. Meta-
regression failed to provide evidence of a significant effect
between outcome and study type (retrospective vs. pro-
spective) (P= 0.87) or BMI (P= 0.20).Caesarean section rate
There were 10 studies, involving 899 women with PCOS
and 5401 controls eligible for the meta-analysis of caesarean
section. No significant increased of delivering by caesarean
section was observed in PCOS women, though still with
significant between-study heterogeneity [10 studies, random
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0.000, I2= 99.2%; Figure 7]. Significant publication bias
was detected by the Egger test (P= 0.03). Sensitivity
analysis did substantially decrease insignificant heterogeneity
(χ2: P= 0.748, I2= 0.0%) with the exclusion of one study
with borderline eligibility [42] so that a significantly higher
risk of delivery by caesarean section was discovered in
women with PCOS vs. controls [9 studies, fixed effects
OR 1.74 (95% CI: 1.38–2.11) Figure 2]. Meta-regression
failed to provide evidence of a significant effect between
outcome and study type (retrospective vs. prospective)
(P= 0.87) or BMI (P= 0.20).
Admission to an NICU
There were 5 studies, involving 899 women with PCOS
and 5401 controls eligible for the meta-analysis. InfantsFigure 7 OR for incidence of caesarean section in women with PCOS
02 borderline eligible studies excluded.from women with PCOS demonstrated a significantly higher
rate of admission to a NICU, and heterogeneity was not
found [5 studies, fixed effects OR 2.32 (95% CI: 1.40–3.85)
heterogeneityχ2: P= 0.678, I2= 0.0%; Figure 8]. Significant
publication bias was not detected using the Egger test
(P= 0.40), however, this result should be further investi-
gated due to the small numbers included.
Discussion
The present systematic review summarizes the data from
cohort, case–controlled trials that have evaluated the
risks during pregnancy and neonatal outcomes in woman
with PCOS (GDM, PIH, PE, preterm, birth weight, caesar-
ean section rate, admission to an NICU). A meta-analysis
of the best evidence available was done in order to ob-
tain convincing results for the incidence of such seriousand controls. 01 Incidence of caesarean section all studies included.
Figure 8 OR for incidence of admission to an NICU in women with PCOS and controls.
Qin et al. Reproductive Biology and Endocrinology 2013, 11:56 Page 12 of 14
http://www.rbej.com/content/11/1/56complications during pregnancy. This meta-analysis shows
that insignificant between-study heterogeneity detected,
women with PCOS demonstrated significantly elevated risk
of gestational diabetes mellitus, pregnancy-induced hyper-
tension, preeclampsia, premature delivery, preterm, cae-
sarean section rate, admission to an NICU pregnancy
compared with controls, and marginally significant lower
birth weight in PCOS group is found out. However, the
results of previous meta-analytic data showed that no
increased risk of caesarean section rate in women with
PCOS compared with controls, and birth weight was al-
most the same in the both groups. Other findings of the
present meta-analysis were similar with the results of
previous meta-analytic data.
An issue with the meta-analysis was the significantly
high heterogeneity, thus a series of measures were taken
in the present analysis to guarantee synthesis of the best
available evidence: well-defined inclusion and exclusion
criteria, the Egger test for publication bias, sensitivity ana-
lysis, and meta-regression modeling. Caution is always
required when checking the efficacy of these attempts.
Finally, high-quality data with insignificant heterogen-
eity was successfully obtained by means of sensitivity
analysis by excluding the studies with borderline eligi-
bility (Damant et al., 1982; Wortsman et al., 1991; Turhan
et al., 2003; Haakova et al., 2003; Al-Ojaimi et al., 2006;
Hu et al., 2007; Maliqueo et al., 2009; Han et al., 2011;
Roos et al., 2011). In spite of this, other potential confounding
variables (pre-pregnancy BMI, multiple pregnancy rate,
selection of controls and study design) cannot be over-
looked. The main restriction for this analysis is that con-
natural bias of non-experimental studies (case–control
and cohort), for a deficiency of randomization andconcealment, are easily impacted by any visible or invis-
ible confounding variables.
It should be noted that all the studies included did not
suggest higher multiple pregnancy rates in PCOS com-
pared with control group. Multiple pregnancy is consid-
ered to be one of the most important adverse outcomes
in patients who required the infertility treatment of assisted
reproductive technologies (ART) and ovulation induc-
tion. Till nowadays, negative obstetric complications
associated with multiple gestations have been well docu-
mented, including increased risk of pregnancy-induced
hypertension, preeclampsia, preterm labour, postpartum
hemorrhage, urinary tract infection, neonatal mortality
and cesarean delivery [46,47]. Regarding effect of current
methods in infertility treatment, Altieri & Gambineri
reported that the requirement of assisted reproductive
technology in PCOS patients did not show a statistically
significant increased risk of negative pregnancy and birth
complications [40]. On the other hand, metformin treat-
ment throughout pregnancy in PCOS women increased
risk for prematurity, decreased spontaneous abortion rate
and gestational diabetes, which could be observed great
affect on pregnancy and post-partum complications [48].
Meta-regression was conducted to examine evidence
of effect on obstetric complications according to study
type (retrospective vs. prospective) and BMI (matched or
not), but the results of the two covariates did not show
any beneficial for detecting source of heterogeneity. It
should be noted that an independent risk factor found
for pregnancy and neonatal complications was obesity,
which frequently coexists with PCOS [49]. Nevertheless,
meta-regression women depend on “lean” versus “obese”
cannot be achieved. For eligible studies only refer to the
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not divided the women into “lean” versus “obese”. In
addition, increased prevalence of early pregnancy loss,
birth of small-for-gestational-age, congenital malformations
and pathological jaundice of newborn are analysed as
outcome measures in some individual literatures. These
obstetric complications are not included in the present
analysis because of the small number of relevant literatures.
The major strength of this meta-analysis is the large
number of eligible studies reviewed, and makes it pos-
sible to convert markedly significant heterogeneity to in-
significant by checking the influence of each literature
through sensitivity analysis. This is the most meaningful
point that guaranteed synthesis of the best available evi-
dence. In addition, influence of metformin therapy and
the most potential confounding variables of multiple preg-
nancies on PCOS patients are eliminated, which play an
important role on obstetric complications. Nonetheless,
limitations of the analysis in the present study still exist.
There is insufficient evidence to establish the real cause
of adverse pregnancy and neonatal complications among
women with PCOS, yet fail to provide the independent
risk factor for indicating effect on the chance of develop-
ing such adverse complications. But Veltman-Verhulst has
found that low plasma sex hormone-binding globulin
(SHBG) levels may be a better predictor for GDM in
women presenting with PCOS [50]. In addition, it was
not possible to account for how the prevalence of preg-
nancy and neonatal complications changes follow the
phenotypic variants of PCOS, as the eligible studies
lacked of the stratification of different PCOS phenotype.
Conclusions
In conclusion, women with PCOS are at increased risk
of adverse pregnancy and neonatal complications; this
information may be vital in clinical practice for the
management of pregnancy in women with PCOS. These
women should be given notice of the additional risks
their pregnancies may have, stronger surveillance and
attention should be provided, as well as screening for
these complications during pregnancy and parturition.
However, in order to manage pregnancy in woman with
PCOS more effectively, further investigation into the
importance of glucose control, hormonal status regula-
tion, lifestyle modification and medical therapy among
women with polycystic ovary syndrome during pregnancy
should be done.
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